Skip to main content

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication

Clinical Trial Grant
Duke Scholars

Awarded By

Alnylam Pharmaceuticals

Start Date

May 26, 2022

End Date

October 6, 2025
 

Awarded By

Alnylam Pharmaceuticals

Start Date

May 26, 2022

End Date

October 6, 2025